Protein degraders, also known as proteolysis targeting chimeras (PROTACs), are bifunctional small molecules that bring an E3 ubiquitin ligase and a protein of interest (POI) into proximity, thus promoting ubiquitination and degradation of the targeted POI [1-3]. Despite their great promise as next-generation pharmaceutical drugs, the development of new PROTACs is challenged by the complexity of the system, which involves binary and ternary interactions between components. Here, we demonstrate the strength of native mass spectrometry (nMS), a label-free technique, to provide novel insight into PROTAC-mediated protein interactions. We show that nMS can monitor the formation of ternary E3-PROTAC-POI complexes and detect various intermediate species in a single experiment. A unique benefit of the method is its ability to reveal preferentially formed E3-PROTAC-POI combinations in competition experiments with multiple substrate proteins, thereby positioning it as an ideal high-throughput screening strategy during the development of new PROTACs.The development of PROTACs, small molecule "protein degraders" (Fig. 1a), is an emerging strategy in drug discovery, having major advantages over traditional small molecule inhibitors.PROTACs eliminate a target protein rather than inhibit it and function in a catalytic manner, requiring sub-stoichiometric amounts to achieve efficiency [4]. Moreover, PROTACs are applicable to a wider spectrum of proteins since degradation is not limited to a specific functional domain or active site [5]. To date, protein degraders have been developed against a variety of medically relevant proteins, such as the tumorigenic Androgen Receptor and Estrogen Receptor, as explored in first clinical trials [5][6][7][8][9][10]. In order to realise the full potential